Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors.

@article{Dienstmann2014PickingTP,
  title={Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors.},
  author={Rodrigo Dienstmann and Jordi Rod{\'o}n and Violeta Serra and Josep Tabernero},
  journal={Molecular cancer therapeutics},
  year={2014},
  volume={13 5},
  pages={1021-31}
}
The frequent activation of the PI3K/AKT/mTOR pathway in cancer, and its crucial role in cell growth and survival, has made it a much desired target for pharmacologic intervention. Following the regulatory approval of the rapamycin analogs everolimus and temsirolimus, recent years have seen an explosion in the number of phosphoinositide 3-kinase (PI3K) pathway inhibitors under clinical investigation. These include: ATP-competitive, dual inhibitors of class I PI3K and mTORC1/2; "pan-PI3K… CONTINUE READING
Highly Influential
This paper has highly influenced 11 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 102 extracted citations

Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2016
View 10 Excerpts
Highly Influenced

PI-3 kinase p110β: a therapeutic target in advanced prostate cancers.

American journal of clinical and experimental urology • 2014
View 4 Excerpts
Highly Influenced

Emerging Role of MicroRNAs in mTOR Signaling

Cellular and Molecular Life Sciences • 2017
View 5 Excerpts
Highly Influenced

Triterpenes in cancer: significance and their influence

Molecular Biology Reports • 2016
View 3 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 88 references

A phase I dose-escalation study to evaluate GDC-0941, a pan-PI3K inhibitor, administered QD or BID in patients with advanced or metastatic solid tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2011
View 5 Excerpts
Highly Influenced

A pilot study of sirolimus (S) in subjects with Cowden Differentiating PI3K/AKT/mTOR Pathway Inhibitors www.aacrjournals.org Mol Cancer Ther

T Komiya, G Blumenthal, +3 authors S Fioravanti
May 2014 1029 on August • 2014

Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d, in patients with Mol Cancer Ther; 13(5) May 2014 Molecular Cancer Therapeutics

SE Coutre, JC Byrd, +3 authors ND WagnerJohnston
Dienstmann et al. on August • 2014

AZD8186: a potent selective inhibitor of PI3Kb targeting PTEN-deficient tumours dependent on dysregulated PI3Kb signalling

U Hancox, S Cosulich, +3 authors B Barlaam
Cancer Res • 2013
View 1 Excerpt

Final results of a phase I study of idelalisib (GS-1101) a selective inhibitor of PI3Kd, in patients with relapsed or refractory CLL

J Brown, FurmanR, +3 authors B Kahl
J Clin Oncol • 2013
View 1 Excerpt

Similar Papers

Loading similar papers…